Is Intellia Therapeutics (NTLA) A Great Investment Pick?

Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” second quarter 2021 investor letter – a copy of which can be downloaded here. Small-cap stocks extended their recent run of success in the second quarter, advancing for the fifth consecutive quarter following the selloff in the early stages of the pandemic. Among the two style indexes, the Russell 2000® Growth Index (up 3.92%) lagged its Russell 2000® Value Index (up 4.56%) counterpart once again in the period, in what has become a common theme as of late. Individual sector returns across the Russell 2000 Growth were nearly all positive, with energy (up 24.93%) leading the way, despite its relatively modest weighting in the benchmark You can take a look at the fund’s top 5 holdings to have an idea about their top bets for 2021.

In the Q2 2021 investor letter of Carillon Tower Advisers, the fund mentioned Intellia Therapeutics, Inc. (NASDAQ: NTLA) and discussed its stance on the firm. Intellia Therapeutics, Inc. is a Cambridge, Massachusetts-based biotechnology company with a $10.9 billion market capitalization. NTLA delivered an impressive 174.97% return since the beginning of the year, while its 12-month returns are massively up by 536.26%. The stock closed at $153.85 per share on September 16, 2021.

Here is what Carillon Tower Advisers has to say about Intellia Therapeutics, Inc. in its Q2 2021 investor letter:

Intellia Therapeutics is a clinical-stage genome editing company focused on the development of proprietary, potentially curative therapeutics. The company’s stock soared after announcing positive interim data from an ongoing phase 1 clinical study of its in vivo gene editing candidate, which is being developed as a single-dose treatment for hereditary transthyretin (ATTR) amyloidosis. This specific form of therapy would be the first of its kind resulting in the precision editing of a gene in a target tissue in the human body.”

Based on our calculations, Intellia Therapeutics, Inc. (NASDAQ: NTLA) was not able to clinch a spot in our list of the 30 Most Popular Stocks Among Hedge Funds. NTLA was in 41 hedge fund portfolios at the end of the first half of 2021, compared to 29 funds in the previous quarter. Intellia Therapeutics, Inc. (NASDAQ: NTLA) delivered a 94.94% return in the past 3 months.

Hedge funds’ reputation as shrewd investors has been tarnished in the last decade as their hedged returns couldn’t keep up with the unhedged returns of the market indices. Our research has shown that hedge funds’ small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by 115 percentage points since March 2017 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter.

At Insider Monkey, we scour multiple sources to uncover the next great investment idea. For example, Federal Reserve has been creating trillions of dollars electronically to keep the interest rates near zero. We believe this will lead to inflation and boost real estate prices. So, we recommended this real estate stock to our monthly premium newsletter subscribers. We go through lists like the 10 best EV stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage.

Disclosure: None. This article is originally published at Insider Monkey.